NICE u-turn on Novartis’ migraine drug Aimovig
New analyses submitted by Novartis has helped to secure a NICE recommendation for NHS funding
Read More
Tag: erenumab
New data back long-term use of Novartis’ Aimovig in migraine
The data add to real world and long-term evidence showing efficacy of Aimovig for migraine prevention across the migraine spectrum
Read More
Novartis’ Aimovig unlikely to be NHS funded for migraine
NICE has published final draft guidelines rejecting the drug in this setting
Read More
Novartis confirms long-term efficacy, safety of Aimovig
Back in April the SMC accepted the drug for use in patients with chronic migraine.
Read More
Novartis’ Aimovig leads CHMP recommendations
The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed nine medicines for approval at its May meeting, including Novartis’ Aimovig, the first human monoclonal antibody for migraine prevention.
Read More
US OK’s first-in-class drug Aimovig for migraine prevention
Amgen and Novartis’ Aimovig has become the first anti-CGRP therapy to win regulatory clearance in the US, winning approval for migraine prevention.
Read More
Amgen, Novartis’ migraine therapy impresses again
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Read More
Stellar results for Novartis, Teva anti-CGRP migraine drugs
The New England Journal of Medicine has published two separate studies showing that CGRP-targeting therapies – namely Novartis’ erenumab and Teva’s fremanezumab – significantly cut the number of headache days in patients with episodic or chronic migraine, respectively.
Read More
EU regulators review Novartis’ migraine drug
An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
Read More
Novartis/Amgen migraine drug hits late-stage goals
An experimental therapy being developed by Amgen and Novartis to prevent chronic migraine has hit its primary targets in a late-stage trial, further raising hopes for a new treatment option for the condition.
Read More
Amgen/Novartis migraine drug shows promise in trial
An experimental therapy being developed by Amgen and Novartis to prevent chronic migraine has hit its primary targets, confirming safety and efficacy in patients over the 12-week treatment period.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
